163 related articles for article (PubMed ID: 35787856)
1. Incidence and Risk Factors for Acute Kidney Injury After Chimeric Antigen Receptor T-Cell Therapy.
Farooqui N; Sy-Go JPT; Miao J; Mehta R; Vaughan LE; Bennani NN; Wang Y; Bansal R; Hathcock MA; Hayman SR; Johnston PB; Villasboas JC; Paludo J; Ansell SM; Leung N; Lin Y; Herrmann SM
Mayo Clin Proc; 2022 Jul; 97(7):1294-1304. PubMed ID: 35787856
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of CD19-Targeted Chimeric Antigen Receptor T Cell Therapy for Patients with Reduced Renal Function Including Dialysis.
Wood AC; Perez AP; Arciola B; Patel K; Johnson G; DiMaggio E; Bachmeier CA; Reid K; Carallo S; Vargas MH; Faramand R; Chavez JC; Shah B; Gaballa S; Khimani F; Elmariah H; Nishihori T; Lazaryan A; Freeman C; Davila ML; Locke FL; Mhaskar R; Bassil C; Jain MD
Transplant Cell Ther; 2022 Dec; 28(12):829.e1-829.e8. PubMed ID: 36174934
[TBL] [Abstract][Full Text] [Related]
3. Acute Kidney Injury after CAR-T Cell Therapy: Low Incidence and Rapid Recovery.
Gutgarts V; Jain T; Zheng J; Maloy MA; Ruiz JD; Pennisi M; Jaimes EA; Perales MA; Sathick J
Biol Blood Marrow Transplant; 2020 Jun; 26(6):1071-1076. PubMed ID: 32088364
[TBL] [Abstract][Full Text] [Related]
4. Acute Kidney Injury and Electrolyte Abnormalities After Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Diffuse Large B-Cell Lymphoma.
Gupta S; Seethapathy H; Strohbehn IA; Frigault MJ; O'Donnell EK; Jacobson CA; Motwani SS; Parikh SM; Curhan GC; Reynolds KL; Leaf DE; Sise ME
Am J Kidney Dis; 2020 Jul; 76(1):63-71. PubMed ID: 31973908
[TBL] [Abstract][Full Text] [Related]
5. Risk factors of acute kidney injury during BCMA CAR-T cell therapy in patients with relapsed/refractory multiple myeloma.
Lyu Y; Zhang M; Wei G; Ding S; Hu Y; Huang H
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 51(2):137-143. PubMed ID: 36161296
[TBL] [Abstract][Full Text] [Related]
6. Impact of Chronic Kidney Disease and Acute Kidney Injury on Safety and Outcomes of CAR T-Cell Therapy in Lymphoma Patients.
Ahmed G; Bhasin-Chhabra B; Szabo A; Shah NN; Longo W; Dhakal B; Chhabra S; D'Souza A; Fenske TS; Hamadani M
Clin Lymphoma Myeloma Leuk; 2022 Nov; 22(11):863-868. PubMed ID: 35934632
[TBL] [Abstract][Full Text] [Related]
7. Transient acute kidney injury after chimeric antigen receptor T-cell therapy in patients with hematological malignancies.
León-Román J; Iacoboni G; Bermejo S; Carpio C; Bolufer M; García-Carro C; Sánchez-Salinas M; Alonso-Martínez C; Bestard O; Barba P; Soler MJ
Clin Kidney J; 2024 Mar; 17(3):sfae027. PubMed ID: 38500492
[TBL] [Abstract][Full Text] [Related]
8. Incidence and Management of Effusions Before and After CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Large B Cell Lymphoma.
Mirza AS; Kumar A; Hashmi H; Garcia F; Logothetis CN; Darwin A; Faramand R; Reid K; Bachmeier C; Chavez JC; Shah B; Pinilla-Ibarz J; Khimani F; Lazaryan A; Liu H; Davila ML; Nishihori T; Locke FL; Jain MD
Transplant Cell Ther; 2021 Mar; 27(3):242.e1-242.e6. PubMed ID: 33781520
[TBL] [Abstract][Full Text] [Related]
9. Acute kidney injury following treatment with CD19-specific CAR T-cell therapy in children, adolescent and young adult patients with B-cell acute lymphoblastic leukemia.
Petgrave YP; Selukar S; Epperly R; Naik S; Santos ND; Triplett BM; Gottschalk S; Bissler J; Talleur AC
Res Sq; 2023 Oct; ():. PubMed ID: 37886451
[TBL] [Abstract][Full Text] [Related]
10. Acute kidney injury following treatment with CD19-specific CAR T-cell therapy in children, adolescent, and young adult patients with B-cell acute lymphoblastic leukemia.
Petgrave Y; Selukar S; Epperly R; Naik S; Santos ND; Triplett BM; Gottschalk S; Bissler J; Talleur AC
Pediatr Nephrol; 2024 Mar; ():. PubMed ID: 38507119
[TBL] [Abstract][Full Text] [Related]
11. Individual Patient Data Meta-Analysis from 16 Trials for Safety Factors in Cytokine Release Syndrome After CAR-T Therapy in Patients with Non-Hodgkin Lymphoma (NHL) and Acute Lymphoblastic Leukemia.
Li J; Wu Z; Zhao N
Adv Ther; 2019 Oct; 36(10):2881-2894. PubMed ID: 31428935
[TBL] [Abstract][Full Text] [Related]
12. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial.
Jacobson CA; Chavez JC; Sehgal AR; William BM; Munoz J; Salles G; Munshi PN; Casulo C; Maloney DG; de Vos S; Reshef R; Leslie LA; Yakoub-Agha I; Oluwole OO; Fung HCH; Rosenblatt J; Rossi JM; Goyal L; Plaks V; Yang Y; Vezan R; Avanzi MP; Neelapu SS
Lancet Oncol; 2022 Jan; 23(1):91-103. PubMed ID: 34895487
[TBL] [Abstract][Full Text] [Related]
13. IL-10 plus the EASIX score predict bleeding events after anti-CD19 CAR T-cell therapy.
Wang X; Li C; Luo W; Zhang Y; Huang Z; Xu J; Mei H; Hu Y
Ann Hematol; 2023 Dec; 102(12):3575-3585. PubMed ID: 37814134
[TBL] [Abstract][Full Text] [Related]
14. Risk factors of tumor lysis syndrome in relapsed/refractory multiple myeloma patients undergoing BCMA CAR-T cell therapy.
Zhang Q; Zu C; Meng Y; Lyu Y; Hu Y; Huang H
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 51(2):144-150. PubMed ID: 36161293
[TBL] [Abstract][Full Text] [Related]
15. Epidemiology and Predictors of 30-Day Readmission in CAR-T Cell Therapy Recipients.
Sharma A; Singh V; Deol A
Transplant Cell Ther; 2023 Feb; 29(2):108.e1-108.e7. PubMed ID: 36371048
[TBL] [Abstract][Full Text] [Related]
16. Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL.
Roberts ZJ; Better M; Bot A; Roberts MR; Ribas A
Leuk Lymphoma; 2018 Aug; 59(8):1785-1796. PubMed ID: 29058502
[TBL] [Abstract][Full Text] [Related]
17. Low incidence of invasive fungal disease following CD19 chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma.
Little JS; Aleissa MM; Beluch K; Gonzalez-Bocco IH; Marty FM; Manne-Goehler J; Koo S; Hammond SP; Jacobson CA
Blood Adv; 2022 Aug; 6(16):4821-4830. PubMed ID: 35802461
[TBL] [Abstract][Full Text] [Related]
18. Cost-Effectiveness of Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed or Refractory Large B Cell Lymphoma: No Impact of Site of Care.
Cummings Joyner AK; Snider JT; Wade SW; Wang ST; Buessing MG; Johnson S; Gergis U
Adv Ther; 2022 Aug; 39(8):3560-3577. PubMed ID: 35689726
[TBL] [Abstract][Full Text] [Related]
19. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.
Lee DW; Kochenderfer JN; Stetler-Stevenson M; Cui YK; Delbrook C; Feldman SA; Fry TJ; Orentas R; Sabatino M; Shah NN; Steinberg SM; Stroncek D; Tschernia N; Yuan C; Zhang H; Zhang L; Rosenberg SA; Wayne AS; Mackall CL
Lancet; 2015 Feb; 385(9967):517-528. PubMed ID: 25319501
[TBL] [Abstract][Full Text] [Related]
20. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
Front Immunol; 2020; 11():564099. PubMed ID: 33329526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
